Diffusion Magnetic Resonance Imaging (dMRI) in the Early Evaluation of Brain White Matter Diseases

NCT07108712 | Recruiting

• 1 other identifier: HD000235
• Study Type: observational
• Target: 150
• Locations: 1 country
• Sites: 1

Brief Summary

To assess the sensitivity and accuracy of diffusion magnetic resonance imaging (MRI), including diffusion-weighted imaging (DWI) metrics, in identifying early-stage changes in brain white matter related to various white matter diseases.

Conditions

Diffusion Magnetic Resonance Imaging; Brain White Matter Diseases

Outcome Measures

Primary Outcomes (1)

• Sensitivity of diffusion magnetic resonance imaging

  Sensitivity of diffusion magnetic resonance imaging to predict the early evaluation of brain white matter diseases

  Immediately after diffusion magnetic resonance imaging (Up to 1 hour)

Study Arms (1)

Study group

Patients diagnosed with suspected early-stage white matter disease (e.g., multiple sclerosis, small vessel disease, Alzheimer's disease, frontotemporal dementia, leukoaraiosis) will be enrolled.

Other: Magnetic Resonance Imaging (MRI)

Interventions

Magnetic Resonance Imaging (MRI) OTHER

Magnetic Resonance Imaging (MRI) Scanner: All imaging will be performed using a 1.5 tesla MRI scanner to ensure high resolution and signal-to-noise ratio.

Study group

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

This study will be a multicenter, cross-sectional study will be conducted on patients diagnosed with suspected early-stage white matter disease (e.g., multiple sclerosis, small vessel disease, Alzheimer's disease, frontotemporal dementia, leukoaraiosis) will be enrolled. Healthy age-matched controls will also be included for comparison.

You may qualify if:

• Adults aged 18-80 years.
• Clinical suspicion of early-stage white matter disease.
• No prior diagnosis of significant neurological disorders (e.g., stroke, brain tumors).
• Ability to provide informed consent.

You may not qualify if:

• Pregnancy or breastfeeding.
• Contraindications for magnetic resonance imaging (MRI) (e.g., metal implants, pacemakers).
• Severe psychiatric or cognitive impairment that prevents participation.
• Control Group: Healthy individuals without any clinical history of neurological diseases, matched by age and sex to the patient cohort.

Sponsors & Collaborators

• The General Authority for Teaching Hospitals and Institutes: lead

Study Sites (1)

General Authority for Teaching Hospitals and Institutes

Cairo, Egypt

RECRUITING

MeSH Terms

Interventions

Magnetic Resonance Spectroscopy

Intervention Hierarchy (Ancestors)

Spectrum Analysis; Chemistry Techniques, Analytical; Investigative Techniques

Central Study Contacts

Hekmat S Baumey, MD

CONTACT

00201555433546; hekmattsamir@gmail.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: NETWORK
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Lecturer of Diagnostic Radiology, Damnhour National Medical Institute

Study Record Dates

• First Submitted: July 31, 2025
• First Posted: August 7, 2025
• Study Start: May 1, 2025
• Primary Completion: December 1, 2025
• Study Completion: December 1, 2025
• Last Updated: August 7, 2025

Record last verified: 2025-07

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL
• Time Frame: After the end of study for one year.
• Access Criteria: The data will be available upon a reasonable request from the corresponding author.

Locations

EG (1)